Technical Analysis for ATNF - 180 Life Sciences Corp.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.37 | 1.28% | 0.03 |
ATNF closed up 1.28 percent on Thursday, November 21, 2024, on 2 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Flat | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
200 DMA Resistance | Bearish | 1.28% | |
NR7 | Range Contraction | 1.28% | |
NR7-2 | Range Contraction | 1.28% | |
Narrow Range Bar | Range Contraction | 1.28% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 6 hours ago |
Rose Above Previous Day's High | about 6 hours ago |
200 DMA Resistance | about 6 hours ago |
Outside Day | about 6 hours ago |
Down 5% | about 6 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Disease Immunology Pain Inflammation Inflammatory Diseases Cytokine Fibrosis Human Physiology Tumor Necrosis Factor Animal Physiology
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Disease Immunology Pain Inflammation Inflammatory Diseases Cytokine Fibrosis Human Physiology Tumor Necrosis Factor Animal Physiology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 17.75 |
52 Week Low | 1.16 |
Average Volume | 2,509,677 |
200-Day Moving Average | 2.38 |
50-Day Moving Average | 2.70 |
20-Day Moving Average | 3.18 |
10-Day Moving Average | 2.66 |
Average True Range | 0.60 |
RSI (14) | 41.18 |
ADX | 44.47 |
+DI | 45.64 |
-DI | 21.85 |
Chandelier Exit (Long, 3 ATRs) | 4.10 |
Chandelier Exit (Short, 3 ATRs) | 4.02 |
Upper Bollinger Bands | 4.54 |
Lower Bollinger Band | 1.83 |
Percent B (%b) | 0.2 |
BandWidth | 84.90 |
MACD Line | -0.19 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.16 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.64 | ||||
Resistance 3 (R3) | 2.64 | 2.54 | 2.60 | ||
Resistance 2 (R2) | 2.54 | 2.47 | 2.55 | 2.58 | |
Resistance 1 (R1) | 2.46 | 2.43 | 2.50 | 2.46 | 2.57 |
Pivot Point | 2.36 | 2.36 | 2.38 | 2.36 | 2.36 |
Support 1 (S1) | 2.28 | 2.29 | 2.32 | 2.28 | 2.17 |
Support 2 (S2) | 2.18 | 2.25 | 2.18 | 2.16 | |
Support 3 (S3) | 2.10 | 2.18 | 2.14 | ||
Support 4 (S4) | 2.10 |